• Careers
  • News
  • Publications
  • Contact Us
  • Company
    • About Us
    • Management Team
    • Board of Directors
    • Collaborations
    • Careers
    • Contact Us
  • Therapeutic Areas
    • Oncology
    • Cystic Fibrosis
    • Publications
  • Programs
    • Pipeline
    • mTORC1/2 inhibitor Sapanisertib
    • SYK Inhibitor Mivavotinib
    • Arginase Inhibitor
      Cystic Fibrosis
    • Preclinical Programs
  • Clinical Trials
    • Clinical Trials Overview
    • Expanded Access
  • Investors
    • Corporate Profile
    • Press Releases
    • Event & Presentations
    • Stock Information
    • Financial Information
      • Overview
      • SEC Filings
      • Ownership Summary
    • Analyst Coverage
    • Corporate Governance
      • Highlights
      • Board of Directors
      • Management Team
      • Committee Composition
    • Shareholder Services
      • Investor FAQs
      • E-mail Alerts
    • Proxy & Annual Report
    • Contact Us
  • Careers
  • News
  • Publications
  • Contact Us

Sam Whiting, M.D., Ph.D.

Sam Whiting, M.D., Ph.D. is Senior Vice President of Clinical Development. Dr. Whiting joined Calithera in May 2016. Prior to joining Calithera, Dr. Whiting served as Vice President of Research and Clinical Development at Gradalis. Dr. Whiting previously worked in development of small molecule targeted and immune-oncology agents at VentiRx Pharmaceuticals and Oncothyreon. Previously, Dr. Whiting served as Assistant Professor of Medical Oncology at the University of Washington, Assistant Member of Clinical Research at the Fred Hutchinson Cancer Research Center, and Clinical Head of Gastrointestinal Oncology at the Seattle Cancer Care Alliance. Dr. Whiting completed fellowship training in medical oncology at the Fred Hutchinson Cancer Research Center. His training in internal medicine was at the ABIM Research Pathway at the University of Washington. Dr. Whiting received his B.S. with Honors in Chemistry from Lewis and Clark College, and his M.D. and Ph.D. as part of the Medical Scientist Training Program at the University of Washington Medical Center.

Comments

Leave a Reply Cancel reply

You must be logged in to post a comment.

Post navigation

Previous PostPrevious
Next PostNext
Company
  • About Us
  • Management Team
  • Board of Directors
  • Collaborations
  • Careers
  • Contact Us
Therapeutic Areas
  • Oncology
  • Cystic Fibrosis
  • Publications
Programs
  • Pipeline
  • mTORC1/2 inhibitor Sapanisertib
  • SYK Inhibitor Mivavotinib
  • Arginase Inhibitor Cystic Fibrosis
  • Preclinical Programs
Clinical Trials
  • Clinical Trial Overview
  • Expanded Access
Investors
  • Corporate Profile
  • Press Release
  • Events & Presentations
  • Stock Information
  • Financial Information
  • Analyst Coverage
  • Corporate Governance
  • Shareholder Services
  • Proxy & Annual Report
  • Contact Us
© 2022 Calithera Biosciences, Inc. All rights reserved.
ETHICS & COMPLIANCEPRIVACY POLICYLEGAL TERMS OF USE
  • Contact Us
  • News
CALITHERA® and the Calithera logos are trademarks or registered trademarks of Calithera Biosciences, Inc.
CALITHERA® and the Calithera logos are trademarks or registered trademarks of Calithera Biosciences, Inc.